April 15 (Reuters) - Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion.
Paragon, backed by private-equity firms Camden Partners and NewSpring Capital, focuses on developing gene therapy, next-generation vaccines, and other complex biopharmaceuticals for its clients.
The Wall Street Journal reported on Sunday that Catalent had agreed to buy Paragon.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
